These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 18077493)

  • 1. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis.
    Panoulas VF; Douglas KM; Stavropoulos-Kalinoglou A; Metsios GS; Nightingale P; Kita MD; Elisaf MS; Kitas GD
    Rheumatology (Oxford); 2008 Jan; 47(1):72-5. PubMed ID: 18077493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis.
    Panoulas VF; Douglas KM; Milionis HJ; Stavropoulos-Kalinglou A; Nightingale P; Kita MD; Tselios AL; Metsios GS; Elisaf MS; Kitas GD
    Rheumatology (Oxford); 2007 Sep; 46(9):1477-82. PubMed ID: 17704521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross-sectional study.
    Toms TE; Panoulas VF; Douglas KM; Griffiths HR; Kitas GD
    Arthritis Res Ther; 2008; 10(6):R145. PubMed ID: 19091101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum uric acid is independently associated with hypertension in patients with rheumatoid arthritis.
    Panoulas VF; Douglas KM; Milionis HJ; Nightingale P; Kita MD; Klocke R; Metsios GS; Stavropoulos-Kalinoglou A; Elisaf MS; Kitas GD
    J Hum Hypertens; 2008 Mar; 22(3):177-82. PubMed ID: 17960169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantifying cutaneous adverse effects of systemic glucocorticoids in patients with rheumatoid arthritis: a cross-sectional cohort study.
    Amann J; Wessels AM; Breitenfeldt F; Huscher D; Bijlsma JWJ; Jacobs JWG; Buttgereit F
    Clin Exp Rheumatol; 2017; 35(3):471-476. PubMed ID: 28094753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose relationship between oral glucocorticoids and tumor necrosis factor inhibitors and the risk of hospitalized infectious events among patients with rheumatoid arthritis.
    Schenfeld J; Iles J; Trivedi M; Accortt NA
    Rheumatol Int; 2017 Jul; 37(7):1075-1082. PubMed ID: 28255642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral glucocorticoid therapy and all-cause and cause-specific mortality in patients with rheumatoid arthritis: a retrospective cohort study.
    Movahedi M; Costello R; Lunt M; Pye SR; Sergeant JC; Dixon WG
    Eur J Epidemiol; 2016 Oct; 31(10):1045-1055. PubMed ID: 27256352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target organ damage in patients with rheumatoid arthritis: the role of blood pressure and heart rate.
    Panoulas VF; Toms TE; Metsios GS; Stavropoulos-Kalinoglou A; Kosovitsas A; Milionis HJ; Douglas KM; John H; Kitas GD
    Atherosclerosis; 2010 Mar; 209(1):255-60. PubMed ID: 19781703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study.
    Davis JM; Maradit Kremers H; Crowson CS; Nicola PJ; Ballman KV; Therneau TM; Roger VL; Gabriel SE
    Arthritis Rheum; 2007 Mar; 56(3):820-30. PubMed ID: 17330254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is the prevalence of arterial hypertension in rheumatoid arthritis and osteoarthritis associated with disease?
    Morović-Vergles J; Salamon L; Marasović-Krstulović D; Kehler T; Sakić D; Badovinac O; Vlak T; Novak S; Stiglić-Rogoznica N; Hanih M; Bedeković D; Grazio S; Kadojić M; Milas-Ahić J; Prus V; Stamenković D; Sošo D; Anić B; Babić-Naglić D; Gamulin S
    Rheumatol Int; 2013 May; 33(5):1185-92. PubMed ID: 22965673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucose tolerance, insulin sensitivity and β-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids.
    Hoes JN; van der Goes MC; van Raalte DH; van der Zijl NJ; den Uyl D; Lems WF; Lafeber FP; Jacobs JW; Welsing PM; Diamant M; Bijlsma JW
    Ann Rheum Dis; 2011 Nov; 70(11):1887-94. PubMed ID: 21908880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comorbidities in patients with psoriatic arthritis: a comparison with rheumatoid arthritis and psoriasis.
    Nas K; Karkucak M; Durmus B; Karatay S; Capkın E; Kaya A; Ucmak D; Akar ZA; Cevik R; Kilic E; Kilic G; Ozgocmen S
    Int J Rheum Dis; 2015 Nov; 18(8):873-9. PubMed ID: 26173043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis.
    del Rincón I; Battafarano DF; Restrepo JF; Erikson JM; Escalante A
    Arthritis Rheumatol; 2014 Feb; 66(2):264-72. PubMed ID: 24504798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current limitations in the management of cardiovascular risk in rheumatoid arthritis.
    Scott IC; Ibrahim F; Johnson D; Scott DL; Kingsley GH
    Clin Exp Rheumatol; 2012; 30(2):228-32. PubMed ID: 22325679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction.
    den Uyl D; van Raalte DH; Nurmohamed MT; Lems WF; Bijlsma JW; Hoes JN; Dijkmans BA; Diamant M
    Arthritis Rheum; 2012 Mar; 64(3):639-46. PubMed ID: 21953589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incident comorbidity among patients with rheumatoid arthritis treated or not with low-dose glucocorticoids: a retrospective study.
    Mazzantini M; Talarico R; Doveri M; Consensi A; Cazzato M; Bazzichi L; Bombardieri S
    J Rheumatol; 2010 Nov; 37(11):2232-6. PubMed ID: 20843913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and Risk of Glucocorticoid-Associated Adverse Effects in Patients With Rheumatoid Arthritis.
    Wilson JC; Sarsour K; Gale S; Pethö-Schramm A; Jick SS; Meier CR
    Arthritis Care Res (Hoboken); 2019 Apr; 71(4):498-511. PubMed ID: 29856128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rheumatoid arthritis is an independent risk factor for an increased augmentation index regardless of the coexistence of traditional cardiovascular risk factors.
    Pieringer H; Brummaier T; Schmid M; Pichler M; Hayat-Khayyati A; Ebner S; Biesenbach G; Pohanka E
    Semin Arthritis Rheum; 2012 Aug; 42(1):17-22. PubMed ID: 22475246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
    Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
    J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-morbidity in patients with early rheumatoid arthritis - inflammation matters.
    Innala L; Sjöberg C; Möller B; Ljung L; Smedby T; Södergren A; Magnusson S; Rantapää-Dahlqvist S; Wållberg-Jonsson S
    Arthritis Res Ther; 2016 Jan; 18():33. PubMed ID: 26818851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.